174 related articles for article (PubMed ID: 15118275)
41. Native somatostatin sst2 and sst5 receptors functionally coupled to Gi/o-protein, but not to the serum response element in AtT-20 mouse tumour corticotrophs.
Cervia D; Fehlmann D; Hoyer D
Naunyn Schmiedebergs Arch Pharmacol; 2003 Jun; 367(6):578-87. PubMed ID: 12750875
[TBL] [Abstract][Full Text] [Related]
42. The expression of thyrotrophin-releasing hormone receptor 1 messenger ribonucleic acid in human pituitary adenomas.
Kim K; Arai K; Sanno N; Teramoto A; Shibasaki T
Clin Endocrinol (Oxf); 2001 Mar; 54(3):309-16. PubMed ID: 11298082
[TBL] [Abstract][Full Text] [Related]
43. Chronic treatment with estrogen up-regulates expression of sst2 messenger ribonucleic acid (mRNA) but down-regulates expression of sst5 mRNA in rat pituitaries.
Kimura N; Tomizawa S; Arai KN; Kimura N
Endocrinology; 1998 Apr; 139(4):1573-80. PubMed ID: 9528936
[TBL] [Abstract][Full Text] [Related]
44. Impact of gsp oncogene on the expression of genes coding for Gsalpha, Pit-1, Gi2alpha, and somatostatin receptor 2 in human somatotroph adenomas: involvement in octreotide sensitivity.
Barlier A; Pellegrini-Bouiller I; Gunz G; Zamora AJ; Jaquet P; Enjalbert A
J Clin Endocrinol Metab; 1999 Aug; 84(8):2759-65. PubMed ID: 10443675
[TBL] [Abstract][Full Text] [Related]
45. Resistance to somatostatin (SRIH) analog therapy in acromegaly. Re-evaluation of the correlation between the SRIH receptor status of the pituitary tumor and the in vivo inhibition of GH secretion in response to SRIH analog.
Bertherat J; Chanson P; Dewailly D; Enjalbert A; Jaquet P; Kordon C; Peillon F; Timsit J; Epelbaum J
Horm Res; 1992; 38(1-2):94-9. PubMed ID: 1306525
[TBL] [Abstract][Full Text] [Related]
46. Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly.
Amato G; Mazziotti G; Rotondi M; Iorio S; Doga M; Sorvillo F; Manganella G; Di Salle F; Giustina A; Carella C
Clin Endocrinol (Oxf); 2002 Jan; 56(1):65-71. PubMed ID: 11849248
[TBL] [Abstract][Full Text] [Related]
47. Octreotide as primary therapy for acromegaly.
Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
[TBL] [Abstract][Full Text] [Related]
48. Characteristics of acromegalic patients with a good response to octreotide, a somatostatin analogue.
Yang IM; Woo JT; Kim SW; Kim JW; Kim YS; Choi YK
Clin Endocrinol (Oxf); 1995 Mar; 42(3):295-301. PubMed ID: 7758235
[TBL] [Abstract][Full Text] [Related]
49. Long-term in-vitro treatment of human growth hormone (GH)-secreting pituitary adenoma cells with octreotide causes accumulation of intracellular GH and GH mRNA levels.
Hofland LJ; Velkeniers B; vd Lely AJ; van Koetsveld PM; Kazemzadeh M; Waaijers M; Hooghe-Peters EL; Lamberts SW
Clin Endocrinol (Oxf); 1992 Sep; 37(3):240-8. PubMed ID: 1424206
[TBL] [Abstract][Full Text] [Related]
50. Growth hormone response to the hypothalamic somatostatinergic activity in acromegalic patients.
Yang I; Park S; Woo J; Kim S; Kim J; Kim Y; Choi Y
J Clin Endocrinol Metab; 1997 Aug; 82(8):2492-6. PubMed ID: 9253323
[TBL] [Abstract][Full Text] [Related]
51. Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study.
Bertherat J; Tenenbaum F; Perlemoine K; Videau C; Alberini JL; Richard B; Dousset B; Bertagna X; Epelbaum J
J Clin Endocrinol Metab; 2003 Nov; 88(11):5353-60. PubMed ID: 14602773
[TBL] [Abstract][Full Text] [Related]
52. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile.
Bruns C; Lewis I; Briner U; Meno-Tetang G; Weckbecker G
Eur J Endocrinol; 2002 May; 146(5):707-16. PubMed ID: 11980628
[TBL] [Abstract][Full Text] [Related]
53. Distinct patterns of expression and physiological effects of sst1 and sst2 receptor subtypes in mouse hypothalamic neurons and astrocytes in culture.
Viollet C; Lanneau C; Faivre-Bauman A; Zhang J; Djordjijevic D; Loudes C; Gardette R; Kordon C; Epelbaum J
J Neurochem; 1997 Jun; 68(6):2273-80. PubMed ID: 9166719
[TBL] [Abstract][Full Text] [Related]
54. Effect of preoperative use of long-acting octreotide on growth hormone secreting pituitary adenoma and transsphenoidal surgery.
Yin J; Su CB; Xu ZQ; Yang Y; Ma WB; Tao W; Yang Z; Xia XW
Chin Med Sci J; 2005 Mar; 20(1):23-6. PubMed ID: 15844307
[TBL] [Abstract][Full Text] [Related]
55. The pituitary uptake of (111)In-DTPA-D-Phe1-octreotide in the normal pituitary and in pituitary adenomas.
Colao A; Lastoria S; Ferone D; Varrella P; Marzullo P; Pivonello R; Cerbone G; Acampa W; Salvatore M; Lombardi G
J Endocrinol Invest; 1999 Mar; 22(3):176-83. PubMed ID: 10219884
[TBL] [Abstract][Full Text] [Related]
56. Prevalence of Gs alpha mutations in Korean patients with pituitary adenomas.
Kim HJ; Kim MS; Park YJ; Kim SW; Park DJ; Park KS; Kim SY; Cho BY; Lee HK; Jung HW; Han DH; Lee HS; Chi JG
J Endocrinol; 2001 Feb; 168(2):221-6. PubMed ID: 11182759
[TBL] [Abstract][Full Text] [Related]
57. Somatostatin receptors on thyrotropin-secreting pituitary adenomas: comparison with the inhibitory effects of octreotide upon in vivo and in vitro hormonal secretions.
Bertherat J; Brue T; Enjalbert A; Gunz G; Rasolonjanahary R; Warnet A; Jaquet P; Epelbaum J
J Clin Endocrinol Metab; 1992 Aug; 75(2):540-6. PubMed ID: 1353505
[TBL] [Abstract][Full Text] [Related]
58. Somatostatin receptor scintigraphy in patients with pituitary adenoma.
Rieger A; Rainov NG; Elfrich C; Klaua M; Meyer H; Lautenschläger C; Burkert W; Mende T
Neurosurg Rev; 1997; 20(1):7-12. PubMed ID: 9085281
[TBL] [Abstract][Full Text] [Related]
59. In vivo secretory potential and the effect of combination therapy with octreotide and cabergoline in patients with clinically non-functioning pituitary adenomas.
Andersen M; Bjerre P; Schrøder HD; Edal A; Høilund-Carlsen PF; Pedersen PH; Hagen C
Clin Endocrinol (Oxf); 2001 Jan; 54(1):23-30. PubMed ID: 11167922
[TBL] [Abstract][Full Text] [Related]
60. Ghrelin mRNA and GH secretagogue receptor mRNA in human GH-producing pituitary adenomas is affected by mutations in the alpha subunit of G protein.
Kim K; Sanno N; Arai K; Takano K; Yasufuku-Takano J; Teramoto A; Shibasaki T
Clin Endocrinol (Oxf); 2003 Nov; 59(5):630-6. PubMed ID: 14616888
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
